We could not find any results for:
Make sure your spelling is correct or try broadening your search.
ChromaDex Corp is a bioscience company dedicated to healthy aging. The ChromaDex team is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. The company is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship in... ChromaDex Corp is a bioscience company dedicated to healthy aging. The ChromaDex team is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. The company is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen. Nicotinamide riboside and other NAD+ precursors are protected by ChromaDex's patent portfolio. It delivers Niagen as the sole active ingredient in its consumer product namely, Tru Niagen which is available on Tru Niagen's website and through partnerships with retailers and distributors. Show more
All Tru Niagen products (except Tru Niagen 1,000mg, which is NSF Certified for Sport®) are Alkemist Assured ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine...
Fourth quarter net sales of $21.2 million, gross margin of 61.0%, and net income of $0.1 million. Full year net sales of $83.6 million, up 16% from the prior year, gross margin of 60.8%, net loss...
0001386570FALSE00013865702024-03-062024-03-06UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549FORM 8-KCURRENT REPORTPursuant to Section 13 OR 15(d) of The Securities Exchange...
0001386570falseFY2023http://fasb.org/us-gaap/2023#AccountingStandardsUpdate201613MemberP3Y0.33330.33330.33330.33330.333300013865702023-01-012023-12-3100013865702023-06-30iso4217:USD00013865702024-0...
SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...
SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...
ChromaDex Corp. (NASDAQ:CDXC) (“the Company”), a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, March 6, 2024 at 4:30 p.m. ET to...
ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announced today that it will be participating in Renmark Financial...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.56 | 18.72909699 | 2.99 | 4.0598 | 2.95 | 618664 | 3.63821422 | CS |
4 | 1.84 | 107.602339181 | 1.71 | 4.0598 | 1.57 | 528442 | 2.87653051 | CS |
12 | 2.07 | 139.864864865 | 1.48 | 4.0598 | 1.36 | 223146 | 2.63219821 | CS |
26 | 2.1 | 144.827586207 | 1.45 | 4.0598 | 1.25 | 144153 | 2.28732852 | CS |
52 | 1.97 | 124.683544304 | 1.58 | 4.0598 | 1.25 | 118994 | 1.98743904 | CS |
156 | -5.32 | -59.9774520857 | 8.87 | 11.2 | 1.15 | 322845 | 4.51030493 | CS |
260 | -0.47 | -11.6915422886 | 4.02 | 23.66 | 1.15 | 482803 | 8.39213181 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions